Company Description: Jaya Biosciences (Jaya) is developing targeted gene therapies for impaired lysosome/autophagy function, a critical component in the etiology of severe neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's Disease (PD). Jaya leverages a proprietary human genetics algorithm to diagnose and treat individuals predisposed to AD and PD. The novelty of the technology is the discovery that patients with heterozygous gene deficiencies that cause lysosomal storage diseases have a significantly increased risk of developing severe neurological disease. Jaya has validated an AAV gene replacement therapy for its lead candidate, JB111, in a target-specific AD mouse model. Jaya is seeking funding for the clinical development of JB111 for AD and the advancement of a portfolio of other targeted therapeutic leads to the proof-of-concept stage. Completing the scientific and clinical milestones will establish Jaya’s mechanism-based targeted therapeutics for neurological disease.